Diagenode

H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes


Judes G et al.

AIM:

Here, we investigated how the St Gallen breast molecular subtypes displayed distinct histone H3 profiles.

PATIENTS & METHODS:

192 breast tumors divided into five St Gallen molecular subtypes (luminal A, luminal B HER2-, luminal B HER2+, HER2+ and basal-like) were evaluated for their histone H3 modifications on gene promoters.

RESULTS:

ANOVA analysis allowed to identify specific H3 signatures according to three groups of genes: hormonal receptor genes (ERS1, ERS2, PGR), genes modifying histones (EZH2, P300, SRC3) and tumor suppressor gene (BRCA1). A similar profile inside high-risk cancers (luminal B [HER2+], HER2+ and basal-like) compared with low-risk cancers including luminal A and luminal B (HER2-) were demonstrated.

CONCLUSION:

The H3 modifications might contribute to clarify the differences between breast cancer subtypes.

Tags
Antibody
IP-Star Compact

Share this article

Published
July, 2016

Source

Related product

  • some alt
    B03000002
    IP-Star® Compact Automated System
  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410039-50
    EZH2 polyclonal antibody - Classic
  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410069
    H3K27me3 polyclonal antibody - Classic
  • RFX5-polyclonal-antibody-diagenode
    C15410165
    H3K4ac polyclonal antibody - Classic
  • Histone-Deacetylase-polyclonal-antibody-diagenode
    C15410004
    H3K9ac polyclonal antibody - Classic
  • RFX5-polyclonal-antibody-diagenode
    C15410206
    Rabbit IgG

Events

 See all events

Twitter feed

News

 See all news